AR and posterior cortical atrophy: Considering the role of the AR blockade on the TME, in a phase I study in mHSPC patients with recurrent non-metastatic PCa, tremelimumab (a humanized anti-CTLA-4 antibody) was administered in combination with bicalutamide.